- Home
- ORGO vs ETB Comparison
ORGO vs ETB Comparison
Compare ORGO & ETB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- ETB
- Stock Information
- Founded
- ORGO 1985
- ETB 2005
- Country
- ORGO United States
- ETB United States
- Employees
- ORGO N/A
- ETB N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- ETB Investment Bankers/Brokers/Service
- Sector
- ORGO Health Care
- ETB Finance
- Exchange
- ORGO Nasdaq
- ETB Nasdaq
- Market Cap
- ORGO 539.1M
- ETB 440.0M
- IPO Year
- ORGO N/A
- ETB N/A
- Fundamental
- Price
- ORGO $3.97
- ETB $15.24
- Analyst Decision
- ORGO Buy
- ETB
- Analyst Count
- ORGO 3
- ETB 0
- Target Price
- ORGO $7.33
- ETB N/A
- AVG Volume (30 Days)
- ORGO 717.2K
- ETB 71.8K
- Earning Date
- ORGO 11-06-2025
- ETB 01-01-0001
- Dividend Yield
- ORGO N/A
- ETB 8.23%
- EPS Growth
- ORGO N/A
- ETB N/A
- EPS
- ORGO N/A
- ETB N/A
- Revenue
- ORGO $429,531,000.00
- ETB N/A
- Revenue This Year
- ORGO $2.51
- ETB N/A
- Revenue Next Year
- ORGO $25.45
- ETB N/A
- P/E Ratio
- ORGO N/A
- ETB N/A
- Revenue Growth
- ORGO N/A
- ETB N/A
- 52 Week Low
- ORGO $2.61
- ETB $11.59
- 52 Week High
- ORGO $6.71
- ETB $14.08
- Technical
- Relative Strength Index (RSI)
- ORGO 40.52
- ETB 57.01
- Support Level
- ORGO $3.84
- ETB $15.17
- Resistance Level
- ORGO $4.30
- ETB $15.38
- Average True Range (ATR)
- ORGO 0.18
- ETB 0.15
- MACD
- ORGO 0.00
- ETB 0.01
- Stochastic Oscillator
- ORGO 23.64
- ETB 75.86
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About ETB Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.